Alcami Acquires Tjoapack, Forging an End-to-End Global Pharmaceutical Services Platform

BOSTON, MA and AMSTERDAM, THE NETHERLANDS – May 05, 2026 – In a significant move to consolidate the pharmaceutical services landscape, Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), has completed its acquisition of Tjoapack, a global contract packaging organization. The transaction, announced today, creates a transatlantic entity designed to provide comprehensive, end-to-end solutions for pharmaceutical and biotechnology clients.

The deal marks a strategic masterstroke for Ampersand Capital Partners, the private equity firm that acquired Tjoapack in 2020. Rather than a straightforward exit, the transaction represents an internal portfolio consolidation, as Ampersand is also a key investor in Alcami alongside GHO Capital and The Vistria Group. By facilitating Tjoapack's sale to Alcami, Ampersand is integrating two of its strategic assets to build a more powerful and vertically integrated healthcare services powerhouse.

A Private Equity Play for an Integrated Supply Chain

This acquisition is a prime example of a sophisticated private equity strategy focused on long-term value creation through portfolio synergy. Ampersand Capital Partners first invested in Tjoapack in 2020, partnering with the founder-built Dutch company to aggressively scale its operations and global reach. Under Ampersand's ownership, Tjoapack transformed from a respected European specialist into a transatlantic player.

Key to this expansion was a combination of organic growth and strategic M&A. This included a substantial expansion of its primary packaging facility in Etten Leur, Netherlands, and the pivotal 2021 acquisition of Pharma Packaging Solutions, which established a critical U.S. presence for Tjoapack. Ampersand also guided investments into advanced automation and complex packaging capabilities, particularly for the rapidly growing injectable drug market.

“Tjoapack is a compelling example of Ampersand’s strategy in action,” said David Parker, General Partner at Ampersand. “We identified a founder owned and built business with a strong reputation in the European market, and we partnered with management to build a more global platform by expanding into the US market. We are proud of what the team has accomplished and excited about the future growth prospects for Tjoapack and Alcami joining forces to deliver value to customers.”

By orchestrating this sale to another of its portfolio companies, Ampersand effectively strengthens its investment in Alcami, creating a more robust platform with a significantly wider service offering. This move reflects a growing trend in the life sciences sector where private equity firms are not just buying and selling assets, but actively building integrated platforms to meet evolving market demands for streamlined, single-source suppliers.

Alcami's New Transatlantic Prowess

The integration of Tjoapack fundamentally enhances Alcami's competitive position, transforming it into an end-to-end global CDMO. The acquisition marks Alcami's first major expansion into Europe, establishing a vital transatlantic footprint that provides clients with crucial U.S.-Europe supply chain redundancy. The combined entity now boasts an operational footprint exceeding 1 million square feet and a skilled workforce of over 1,400 people.

Alcami's existing strengths in drug product manufacturing, laboratory services, and cGMP pharma storage are now complemented by Tjoapack's extensive packaging and supply chain expertise. These new capabilities include primary and secondary packaging for oral solid doses in blisters and bottles, as well as highly specialized automated labeling and packaging for sterile injectables like vials, pre-filled syringes, and auto-injectors. Furthermore, the company will now offer kitting, serialization, and complex cold-chain packaging services.

Crucially, the European presence allows the combined company to provide Qualified Person (QP) release services, a regulatory requirement for medicines marketed in the European Union. This enables clients to streamline their global product launches and manage their supply chain through a single, integrated partner, a significant advantage in a market where speed and efficiency are paramount. This enhanced offering positions Alcami to compete more effectively with industry giants such as Catalent, Lonza, and Thermo Fisher Scientific's Patheon division, which have long leveraged their scale and integrated services.

The Path Forward for a Combined Powerhouse

The leadership of the newly expanded organization will be helmed by Patrick Walsh, Alcami's CEO and Chairman, who will assume CEO responsibility for the combined entity. The integration aims to be seamless for customers of both companies, who are promised uninterrupted service while gaining access to a much broader suite of capabilities.

“Ampersand has been an invaluable partner as we scaled Tjoapack into a global organisation,” said Dexter Tjoa, former CEO of Tjoapack. “Their support enabled our U.S. expansion and sustained investment in the capabilities that matter to our customers. Joining Alcami is a logical next step in the company’s development.”

For existing Tjoapack clients, the merger opens the door to Alcami's extensive development and manufacturing resources. For Alcami's current partners, the deal provides access to world-class packaging scale, enhanced supply chain security, and a direct gateway to the European market. By uniting development, manufacturing, and packaging under one roof, the new Alcami aims to reduce complexity, minimize hand-offs, and accelerate the journey of new medicines from the lab to patients across the globe.